Surveillance To Track Progress Toward Poliomyelitis Eradication — Worldwide, 2021–2022

Since the Global Polio Eradication Initiative (GPEI) was established in 1988, the number of wild poliovirus (WPV) cases has declined by >99.9%, and WPV serotypes 2 and 3 have been declared eradicated (1). By the end of 2022, WPV type 1 (WPV1) transmission remained endemic only in Afghanistan and Pakistan (2,3). However, during 2021-2022, Malawi and Mozambique reported nine WPV1 cases that were genetically linked to Pakistan (4,5), and circulating vaccine-derived poliovirus (cVDPV) outbreaks were detected in 42 countries (6). cVDPVs are oral poliovirus vaccine-derived viruses that can emerge after prolonged circulation in populations with low immunity allowing reversion to neurovirulence and can cause paralysis. Polioviruses are detected primarily through surveillance for acute flaccid paralysis (AFP), and poliovirus is confirmed through stool specimen testing. Environmental surveillance, the systematic sampling of sewage and testing for the presence of poliovirus, supplements AFP surveillance. Both surveillance systems were affected by the COVID-19 pandemic's effects on public health activities during 2020 (7,8) but improved in 2021 (9). This report updates previous reports (7,9) to describe surveillance performance during 2021-2022 in 34 priority countries.* In 2022, a total of 26 (76.5%) priority countries met the two key AFP surveillance performance indicator targets nationally compared with 24 (70.6%) countries in 2021; however, substantial gaps remain in subnational areas. Environmental surveillance expanded to 725 sites in priority countries, a 31.1% increase from the 553 sites reported in 2021. High-quality surveillance is critical to rapidly detect poliovirus transmission and enable prompt poliovirus outbreak response to stop circulation. Frequent monitoring of surveillance guides improvements to achieve progress toward polio eradication.

[1]  F. Mahoney,et al.  Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2021–December 2022 , 2023, MMWR. Morbidity and mortality weekly report.

[2]  I. Spicknall,et al.  JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox — United States, May 22, 2022–January 31, 2023 , 2023, MMWR. Morbidity and mortality weekly report.

[3]  R. Link-Gelles,et al.  Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 , 2023, MMWR. Morbidity and mortality weekly report.

[4]  Stuart H. Cohen,et al.  Mpox Infection in Children—Infection Control Implications for Household Contacts , 2023, Open forum infectious diseases.

[5]  T. Shimabukuro,et al.  Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023 , 2023, MMWR. Morbidity and mortality weekly report.

[6]  M. Reynolds,et al.  Mpox in Children and Adolescents: Epidemiology, Clinical Features, Diagnosis, and Management. , 2022, Pediatrics.

[7]  William T. Robinson,et al.  The Effect of Navigation on Linkage to a PrEP Provider Among PrEP-Eligible Men who have Sex with Men in a U.S. Demonstration Project , 2022, AIDS and Behavior.

[8]  Jonathan Bryant-Genevier,et al.  Epidemiologic Features of the Monkeypox Outbreak and the Public Health Response — United States, May 17–October 6, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[9]  Sunanda R. McGarvey,et al.  Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox — United States, May 22–October 10, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[10]  T. Shimabukuro,et al.  Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[11]  S. D. de Paula,et al.  A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development , 2022, Viruses.

[12]  D. Gubler,et al.  The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines , 2022, PLoS neglected tropical diseases.

[13]  O. Diop,et al.  Surveillance to Track Progress Toward Polio Eradication — Worldwide, 2019–2020 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  E. Holmes,et al.  Epidemiologic History and Genetic Diversity Origins of Chikungunya and Dengue Viruses, Paraguay , 2021, Emerging infectious diseases.

[15]  O. Diop,et al.  Impact of COVID-19 Pandemic on Global Poliovirus Surveillance , 2021, MMWR. Morbidity and mortality weekly report.

[16]  T. Monath The Arboviruses: Epidemiology and Ecology , 2019 .

[17]  J. Grey,et al.  Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. , 2018, Annals of epidemiology.

[18]  Sarah Paige,et al.  Multisectoral prioritization of zoonotic diseases in Uganda, 2017: A One Health perspective , 2018, PloS one.

[19]  M. Pallansch,et al.  The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks , 2017, The Journal of infectious diseases.

[20]  F. Destefano,et al.  Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). , 2015, Vaccine.

[21]  Amartya Sen,et al.  Public action and the quality of life in developing countries. , 2009, Oxford bulletin of economics and statistics.

[22]  F. Arenzana‐Seisdedos,et al.  Multidisciplinary Prospective Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Réunion , 2008, PLoS medicine.

[23]  T. Ksiazek,et al.  Highly Sensitive and Broadly Reactive Quantitative Reverse Transcription-PCR Assay for High-Throughput Detection of Rift Valley Fever Virus , 2007, Journal of Clinical Microbiology.

[24]  Jennifer Prah Ruger,et al.  Ethics and governance of global health inequalities , 2006, Journal of Epidemiology and Community Health.

[25]  M. Bouloy,et al.  Rift Valley fever virus. , 2005, Current molecular medicine.

[26]  S. Harper,et al.  [Implicit value judgments in the measurement of health inequalities]. , 2014, Revista panamericana de salud publica = Pan American journal of public health.

[27]  David Heymann Global polio eradication initiative. , 2006, Bulletin of the World Health Organization.